Panitumumab outcome by tumour location analysis
Response rates
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
•
CR, complete response; PR, partial response.
Response rates were generally higher in:
Left- vs right-sided primary tumours
Patients on panitumumab + chemotherapy vs those on comparator
treatments, regardless of primary tumour side
WT
RAS
PRIME
PEAK
Study 181
Pmab +
FOLFOX FOLFOX
Pmab +
FOLFOX
Bev +
FOLFOX
Pmab +
FOLFIRI FOLFIRI
CR + PR, %
Left
68
53
64
57
50
13
Right
42
35
64
50
13
3
